진행성 노인 대장암에 대한 항암요법 = Chemotherapy in Elderly Patients with Colorectal Cancer

다국어 초록 (Multilingual Abstract)

Colorectal cancer (CRC) affects largely elderly populations. However, older patients with CRC are generally excluded from randomized clinical trials, and the healthy subjects who are recruited are not representative of the general elderly patient population. Nevertheless, recent data from clinical trials specifically targeting elderly patients and related subgroup analyses indicate that well-selected elderly patients can have a similar response to that of younger patients. Chronological age should not determine the candidacy for adjuvant or palliative chemotherapy in elderly patients with CRC. The appropriate management of healthy elderly patients would mean that they could receive aggressive chemotherapy in a similar regimen to that of younger patients, whereas the care of frail elderly patients and those with a short life expectancy should focus on palliation. The use of a comprehensive geriatric assessment could allow the use of safe and beneficial chemotherapy regimens in elderly patients with CRC. (Korean J Med 2014;87:530-536)

참고문헌 (Reference)

1 Iwashyna TJ, "fectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer" 20 : 3992-3998, 2002

2 "Statistic Korea"

3 Hochster HS, "Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study" 26 : 3523-3529, 2008

4 National Cancer Institute, "SEER Cancer Statistics Review (CSR) 1975-2011"

5 Fuchs CS, "Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study" 26 : 689-690, 2008

6 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2014" 대한암학회 46 (46): 123-130, 2014

7 Yancik R, "Population aging and cancer: a cross-national concern" 11 : 437-441, 2005

8 Goldberg RM, "Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/ leucovorin administered bimonthly in elderly patients with colorectal cancer" 24 : 4085-4091, 2006

9 Douillard JY, "Panitumumab- FOLFOX4 treatment and RAS mutations in colorectal cancer" 369 : 1023-1034, 2013

10 National Comprehensive Cancer Network, "NCCN Practice Guidelines in Oncology: Senior Adult Oncology"

11 Andre T, "Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer" 350 : 2343-2351, 2004

12 Sorich MJ, "Karapetis CS. Expended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials" 2014

13 Folprecht G, "Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials" 26 : 1443-1451, 2008

14 Wildiers H, "International society of geriatric oncology consensus on geriatric assessment in older patients with cancer" 2014

15 McCleary NJ, "Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database" 31 : 2600-2606, 2013

16 Sastre J, "First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study" 17 : 339-345, 2012

17 Seymour MT, "FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial" 377 : 1749-1759, 2011

18 Folprecht G, "Efficacy of 5-fluorouracil- based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials" 15 : 1330-1338, 2004

19 Cassidy J, "Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies" 136 : 737-743, 2010

20 Sanoff HK, "Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years" 30 : 2624-2634, 2012

21 Jackson NA, "Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study" 115 : 2617-2629, 2009

22 Folprecht G, "Cetuximab and 1st line chemotherapy in elderly and younger patients with metastatic colorectal cancer (mCRC): a pooled analysis of the CRYSTAL and OPUS studies" 21 (21): 597-, 2010

23 Haller DG, "Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer" 29 : 1465-1471, 2011

24 Rothenberg ML, "Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study" 19 : 1720-1726, 2008

25 Feliu J, "Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study" 23 : 3104-3111, 2005

26 Twelves C, "Capecitabine as adjuvant treatment for stage III colon cancer" 352 : 2696-2704, 2005

27 Cassidy J, "Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin" 13 : 566-575, 2002

28 Jessup JM, "Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation" 294 : 2703-2711, 2005

29 Cunningham D, "AVEX study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial" 14 : 1077-1085, 2013

30 Sargent DJ, "A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients" 345 : 1091-1097, 2001